Trial reportDigestive diseases and sciences2010
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure.
Trial report in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Efficacy and safety of tenofovir disoproxil fumarate versus entecavir in the treatment of acute-on-chronic liver failure with hepatitis B: a systematic review and meta-analysis.BMC gastroenterology · 2023Pooled it
- Meta-analysis of the short-term effects of lamivudine treatment for severe chronic hepatitis B.Virology journal · 2013Pooled it
- Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis.PloS one · 2013Pooled it
- Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B.BMC infectious diseases · 2021Trial
- The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure.Hepatology international · 2016Trial
- Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure.World journal of gastroenterology · 2013Trial
- Efficacy of glucocorticoid therapy for severe jaundice patients with drug-induced liver injury or hepatitis B virus-related acute-on-chronic liver failure: a respectively observational study.BMC infectious diseases · 2026Observational
- Sarcopenia is associated with short- and long-term mortality in patients with acute-on-chronic liver failure.Journal of cachexia, sarcopenia and muscle · 2024Article
- ALTA: a simple nutritional prognostic score for patients with hepatitis B virus-related acute-on-chronic liver failure.Frontiers in nutrition · 2024Article
- Animal models applied to acute-on-chronic liver failure: Are new models required to understand the human condition?World journal of clinical cases · 2022Review
- aMAP Score as a Predictor for Long-Term Outcomes in Patients with HBV-Related Acute-on-Chronic Liver Failure.International journal of general medicine · 2022Article
- Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure.Journal of family medicine and primary care · 2021Article
- A novel prognostic model to predict outcome of artificial liver support system treatment.Scientific reports · 2021Article
- Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2020Review
- Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes.Frontiers in microbiology · 2020Review
- Management of Fulminant Hepatitis B.Current infectious disease reports · 2019Review
- Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants.Virology journal · 2017Article
- A comprehensive validation of HBV-related acute-on-chronic liver failure models to assist decision-making in targeted therapeutics.Scientific reports · 2016Article
- Overview on acute-on-chronic liver failure.Frontiers of medicine · 2016Review
- Acute-on-Chronic Liver Failure (ACLF) in Coastal Eastern India: "A Single-Center Experience".Journal of clinical and experimental hepatology · 2016Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with hepatitis B virus (HBV)-associated acute on chronic liver failure (ACLF) is extremely poor.
aimThis study was designed to evaluate the efficacy and safety of nucleoside analogue treatment of patients with HBV-associated ACLF.
methodsWe used a retrospective review of eligible patients from April 2006 to December 2008. Eligible subjects received 0.5 mg entecavir daily until October 2009 (group A), 100 mg lamivudine daily until October 2009 (group B), or no nucleoside analogue (group C). The primary endpoints were three-month survival and the rate of recurrence of HBV-associated ACLF. The secondary endpoints were HBV DNA levels, liver function, the model of end-stage liver disease (MELD) score, and adverse events.
resultsA total of 104 consecutive patients were recruited, and 33, 34, and 37 patients were randomly allocated to groups A, B, and C, respectively. Although no significant difference in three-month survival was observed, levels of HBV DNA and rates of recurrence of HBV-associated ACLF were lower. Liver function and MELD score were not significantly improved despite significantly reduced HBV DNA levels.
conclusionsThese data indicated that nucleoside analogue treatment did not improve the short-term prognosis of patients with HBV-associated ACLF although it was efficacious and safe in the management of HBV DNA levels. Intriguingly and importantly, continuous nucleoside analogue treatment can significantly reduce the rate of recurrence, which might be indicative of the further benefit of long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.